Trial reportJournal of the Chinese Medical Association : JCMA2026
Effects of insulin and exenatide therapy on glycemic control and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia.
Trial report in Journal of the Chinese Medical Association : JCMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess the efficacy of short-term insulin therapy compared with exenatide therapy in glycemic control, remission rate, and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia.
methodsPatients with newly diagnosed type 2 diabetes and a glycated hemoglobin (HbA1c) level >9% were treated with insulin injections for 10 to 14 days, after which oral glucose tolerance tests (OGTTs) were performed. The patients were randomized in an open-label design to receive either insulin therapy or exenatide therapy for a further 24 weeks. The OGTT was repeated 6 months after randomization to re-evaluate β-cell function and insulin sensitivity. The participants were followed for another year to evaluate long-term glycemic control.
resultsWe randomized 40 patients into the insulin group (n = 22) and the exenatide group (n = 18). One patient in the exenatide group withdrew before the intervention, resulting in 22 and 17 patients in the insulin and exenatide groups, respectively. Body weight was significantly higher in the insulin group than in the exenatide group at baseline (75.8 ± 14.3 vs 60.5 ± 12.2 kg, p = 0.011). The mean HbA1c levels were similar between the insulin and exenatide groups at 6 months (6.74 ± 1.12% vs 6.88 ± 0.76%; p = 0.681) and 12 months after randomization (6.62 ± 0.69% vs 7.05 ± 0.72%; p = 0.119). By 1 year after the intervention, the remission rates were 18.2% (n = 4) in the insulin group and 5.9% (n = 1) in the exenatide group ( p = 0.025). The median time to relapse was 6.5 months in the insulin group and 5.0 months in the exenatide group ( p = 0.685). Compared with the exenatide group, the insulin group had better homeostasis model assessment of β-cell function index, insulinogenic index, and total insulin secretion during the OGTT.
conclusionInsulin therapy may improve β-cell function and reduce remission rates compared with exenatide therapy in patients newly diagnosed with type 2 diabetes and severe hyperglycemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.